1. Home
  2. FGI vs KPRX Comparison

FGI vs KPRX Comparison

Compare FGI & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FGI Industries Ltd.

FGI

FGI Industries Ltd.

N/A

Current Price

$3.93

Market Cap

7.5M

Sector

Industrials

ML Signal

N/A

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

HOLD

Current Price

$2.09

Market Cap

8.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FGI
KPRX
Founded
1987
1998
Country
United States
United States
Employees
420
N/A
Industry
Industrial Specialties
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
8.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FGI
KPRX
Price
$3.93
$2.09
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
8.0K
24.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.80
N/A
Revenue Next Year
$6.26
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.46
$1.76
52 Week High
$12.62
$4.18

Technical Indicators

Market Signals
Indicator
FGI
KPRX
Relative Strength Index (RSI) 37.05 47.93
Support Level $3.88 $1.96
Resistance Level $4.65 $2.21
Average True Range (ATR) 0.47 0.09
MACD -0.08 0.01
Stochastic Oscillator 32.89 42.35

Price Performance

Historical Comparison
FGI
KPRX

About FGI FGI Industries Ltd.

FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: